We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENSG:NASDAQThe Ensign Group, Inc. Analysis

Data as of 2026-09-01 - not real-time

$174.02

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind The Ensign Group, Inc. is neutral at $174.01, with no clear ordering between short and long averages. Over a rolling month the price has gained 1.8%. With RSI at 43.3 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $170.00 and resistance around $185.90.
On valuation the read is undervalued — earnings multiple of 27.3 versus a 30.6 sector average, below the peer group. Analyst price targets sit 26.4% above the current price. Revenue is growing at 17.3% on a 6.9% profit margin. The 0.15% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 23.5%, a beta of -0.02 and a maximum drawdown of 31.8%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 5/10 conviction over the longer horizon.

Top Market Events

Healthcare services company The Ensign Group NASDAQ:ENSG .Shares of healthcare services company The Ensign Group NASDAQ:ENSG .Raises 2026 Annual Earnings and Revenue Guidance; Conference Call and Webcast scheduled for July 29, 2026 at 10:00 am...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 182.43
  • MACD momentum is negative
  • Maximum drawdown of 31.8%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 27.3 versus sector average of 30.6
  • Trading below the 200-day average of 182.43
  • Analyst targets imply +26.4% versus the current price

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 27.3 versus sector average of 30.6
  • Analyst targets imply +26.4% versus the current price
  • Revenue growth of +17.3%

Key Metrics & Analysis

Financial Health

Revenue Growth17.30%
Profit Margin6.90%
P/E Ratio27.3
ROE16.97%
ROA5.49%
Debt/Equity92.03
P/B Ratio4.1
Op. Cash Flow$608.4M
Free Cash Flow$280.6M
Industry P/E30.6

Technical Analysis

TrendNeutral
RSI43.3
Support$170.00
Resistance$185.90
MA 20$179.51
MA 50$173.83
MA 200$182.43
MACDBearish
VolumeStable
Fear & Greed Index94.16

Valuation

Fair Value$91.73
Target Price$220.00
Upside/Downside26.43%
GradeUndervalued
TypeGrowth
Dividend Yield0.15%

Risk Assessment

Beta-0.02
Volatility23.53%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.